S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
NASDAQ:INAB

IN8bio News Headlines

$5.50
-0.36 (-6.14%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.40
$5.94
50-Day Range
$5.50
$8.97
52-Week Range
$5.40
$10.32
Volume
11,579 shs
Average Volume
32,992 shs
Market Capitalization
$103.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



IN8bio Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INAB
News Sentiment

0.00

0.29

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INAB Articles
This Week

0

1

INAB Articles
Average Week

Get IN8bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.

IN8bio (NASDAQ:INAB) News Headlines Today

SourceHeadline
finance.yahoo.com logoIN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
finance.yahoo.com - November 16 at 9:12 AM
MarketBeat logoFY2021 EPS Estimates for IN8bio Inc (NASDAQ:INAB) Lifted by B. Riley
americanbankingnews.com - November 15 at 1:58 AM
MarketBeat logoIN8bio (NASDAQ:INAB) Announces Earnings Results
americanbankingnews.com - November 11 at 5:05 PM
finance.yahoo.com logoIN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors
finance.yahoo.com - November 11 at 7:39 AM
finance.yahoo.com logoIN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - November 10 at 8:38 PM
finance.yahoo.com logoIN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
finance.yahoo.com - November 4 at 10:22 AM
nasdaq.com logoHere's Why We're Not Too Worried About IN8bio's (NASDAQ:INAB) Cash Burn Situation
nasdaq.com - November 1 at 3:09 PM
finance.yahoo.com logoPossible turnaround for IN8bio, Inc. (NASDAQ:INAB) insiders, still down US$241k after a US$1.0m shopping spree
finance.yahoo.com - November 1 at 10:07 AM
finance.yahoo.com logoIN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
finance.yahoo.com - October 27 at 9:38 AM
finance.yahoo.com logoIN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021
finance.yahoo.com - October 4 at 9:05 PM
finance.yahoo.com logoIN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - September 10 at 4:20 PM
finance.yahoo.com logoIN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - August 30 at 12:05 PM
benzinga.com logoMizuho Initiates Coverage On IN8bio with Buy Rating, Announces Price Target of $12
benzinga.com - August 26 at 5:40 PM
barrons.com logoIN8bio Inc.
barrons.com - August 21 at 6:56 AM
finance.yahoo.com logoIN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
finance.yahoo.com - August 13 at 2:53 AM
finance.yahoo.com logoIN8bio Announces Pricing of Initial Public Offering
finance.yahoo.com - August 9 at 11:18 PM
finance.yahoo.com logoIN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors
finance.yahoo.com - August 9 at 11:18 PM
Get IN8bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.